MEDI4736 Placebo, DURVALUMAB
BR31
Phase 3 small_molecule active
Quick answer
MEDI4736 Placebo, DURVALUMAB for Completely resected primary stage IB (≥ 4cm), II and IIIA non-small cell lung cancer patients is a Phase 3 program (small_molecule) at CERO THERAPEUTICS HOLDINGS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- CERO THERAPEUTICS HOLDINGS, INC.
- Indication
- Completely resected primary stage IB (≥ 4cm), II and IIIA non-small cell lung cancer patients
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active